Sudapack breaks ground on major PharmaGuard expansion in Erolzheim
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Abdomen-pelvis CT is the nation’s highest-volume CT category
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
The receipt of this order further strengthens the company's position in the global pharmaceutical market
The audit was completed with zero critical and zero major observations
Subscribe To Our Newsletter & Stay Updated